Investor Presentaiton

Key Operational & Financial Highlights 01 Operating EBIDTA for labs started before April 2022 stood @ 28.3% METROPOLIS The Pathology Specialist Operating EBIDTA for Q3FY23 stood at 28.3%, dilution of ~120 bps on account of Lab addition & Network expansion. New Network has contributed ~3% of Revenues for Q3FY23 02 70 Non-Covid growth @ 13% for Q3FY23 Non-Covid growth stood at 13% for Q3FY23 & 15% for 9MFY23 on Y-o-Y basis (excl. revenues for PPP Contracts & Hi-tech acquisition) Non-Covid Volume growth @ 03 13 10% & RPP @ 3% for Q3FY23 Volume growth for Q3FY23 stood at 10% & RPP growth stood at 3% on Y- o-Y basis (excl. volumes for PPP Contracts & Hi-tech acquisition) 50 04 Non-Covid Revenues from North & East up by 29% Revenue from North & East combined grew by 29% for Q3FY23 on Y-o-Y basis 05 50 06 Specialized & Premium Wellness is the fastest growing segments B2C revenue growth in Focus cities @ 16% for Q3FY23 *EBIDTA for Labs started before April 2022 Our Specialized & Premium Wellness segments are the fastest growing segment for Q3FY23 indicating strong Brand Equity & Doctor's Trust on Metropolis Brand Revenue growth for B2C in focus cities stood at 16% for Q3FY23 & 25% for 9MFY23 on Y-o-Y basis; Mumbai & Pune are growing at a faster pace indicating our strength & market share penetration in the core geographies 6

View entire presentation